Your browser doesn't support javascript.
loading
Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute.
Miousse, Isabelle R; Currie, Richard; Datta, Kaushik; Ellinger-Ziegelbauer, Heidrun; French, John E; Harrill, Alison H; Koturbash, Igor; Lawton, Michael; Mann, Derek; Meehan, Richard R; Moggs, Jonathan G; O'Lone, Raegan; Rasoulpour, Reza J; Pera, Renee A Reijo; Thompson, Karol.
Afiliação
  • Miousse IR; Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Currie R; Syngenta Jealotts Hill International Research Centre, Bracknell, Berkshire, UK.
  • Datta K; Celgene Corporation, Summit, NJ, USA.
  • Ellinger-Ziegelbauer H; Toxicology, Bayer Pharma AG, Wuppertal, Germany; Member of the Innovative Medicines Initiative (IMI) BioMARkers & molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR) consortium www.imi-marcar.eu.
  • French JE; National Institute for Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC, USA.
  • Harrill AH; Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Koturbash I; Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Lawton M; Pfizer, Groton, CT, USA.
  • Mann D; Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.
  • Meehan RR; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Member of the Innovative Medicines Initiative (IMI) BioMARkers & molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR) consortium www.imi-marcar.eu.
  • Moggs JG; Discovery and Investigative Safety, Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland; Member of the Innovative Medicines Initiative (IMI) BioMARkers & molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR) consortium www.imi-marcar.eu.
  • O'Lone R; ILSI Health and Environmental Sciences Institute, Washington, D.C., USA.
  • Rasoulpour RJ; Toxicology Environmental Research and Consulting, The Dow Chemical Company, Midland, MI, USA.
  • Pera RA; Montana State University, Bozeman, MT, USA.
  • Thompson K; Division of Applied Regulatory Science, OCP, CDER, US FDA, Silver Spring, MD, USA.
Toxicology ; 335: 11-9, 2015 Sep 01.
Article em En | MEDLINE | ID: mdl-26134581
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Toxicidade / Perfilação da Expressão Gênica / Epigênese Genética Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Toxicidade / Perfilação da Expressão Gênica / Epigênese Genética Idioma: En Ano de publicação: 2015 Tipo de documento: Article